Global EditionASIA 中文雙語Fran?ais
China
Home / China / Latest

New research on drug yields promising results

By Zhang Yangfei | China Daily | Updated: 2020-03-18 08:19
Share
Share - WeChat
A lab assistant tests drugs at a pharmaceutical company in Harbin, capital of Heilongjiang province, on March 4, 2020. [Photo/Xinhua]

Chinese researchers have completed clinical studies of favipiravir, which shows promising clinical efficacy in treating the novel coronavirus pneumonia, Zhang Xinmin, head of the China National Center for Biotechnology Development, said on Tuesday.

Experiments have shown that patients treated with favipiravir recovered more quickly and their lung conditions improved better than patients in the control group, he said.

Some pharmaceutical enterprises have already obtained drug approval from the State Food and Drug Administration for mass production in February, so the supply of favipiravir is guaranteed, he said, adding that researchers have already recommended the drug be included in the treatment plan as soon as possible.

The Third People's Hospital of Shenzhen in Guangdong province conducted a clinical trial on 80 patients, with 35 receiving the drug. The results showed that patients who took favipiravir tested negative within four days of treatment, whereas patients in the control group needed 11 days to test negative.

The lung conditions of 91.4 percent of the treated group improved as shown in chest imaging, compared with 62.2 percent of the control group, Zhang said.

In another experiment on 120 patients conducted by Zhongnan Hospital of Wuhan University in Hubei province, the treated group had a higher recovery rate at the end of the treatment; further, fever reduction and cough relief took less time for them, he added.

In terms of safety, Zhang said, the drug-developed in Japan and approved for marketing there in 2014-has shown no obvious adverse effects.

"In view of the safety, obvious efficacy and availability of the drug, researchers have officially recommended favipiravir to medical teams and suggested it be included in the treatment plan as soon as possible," he said.

Zhang said the research team will further promote the application of their research results in Wuhan and will promote the Chinese treatment plan in response to the current global pandemic situation.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 国模私拍福利一区二区| 日韩欧美亚洲天堂| 大肚子孕妇交xxxgif| 亚洲国产精品久久网午夜 | 免费人成在线观看视频播放| aaa特级毛片| 日本久久久久久中文字幕| 免费理论片51人人看电影| 黄色三级理沦片| 国内自拍青青草| 东京一本一道一二三区| 日韩精品一区二区三区老鸦窝| 亚洲精品乱码久久久久66| 精品福利一区二区三区免费视频| 国产成人午夜高潮毛片| 91噜噜噜在线观看| 日本成本人三级在线观看2018| 免费看黄色软件大全| 香蕉视频免费看| 国产精品特级露脸AV毛片| 久久91精品国产99久久yfo| 激情啪啪精品一区二区| 四虎影院最新域名| 3d无遮挡h肉动漫在线播放| 日本动漫黄观看免费网站| 伊人色综合视频一区二区三区| 欧美丝袜一区二区三区| 强奷乱码中文字幕| 久久国产高清视频| 欧美亚洲国产日韩| 亚洲综合激情另类小说区| 青柠直播视频在线观看网| 国产精品亚洲综合久久| 中国女人一级毛片| 日韩一级在线观看| 亚洲精品午夜国产va久久成人 | 韩国三级中文字幕| 国产真实伦在线观看| 一个人看的www日本高清视频| 束缚强制gc震动调教视频| 再深点灬舒服灬太大了添a|